Financial Performance - Citius Pharmaceuticals reported a net loss of $11.5 million, or ($1.27) per share, for the quarter ended March 31, 2025, compared to a net loss of $8.5 million, or ($1.34) per share, for the same quarter in 2024[13]. - The company incurred a net loss of $21.8 million for the six months ended March 31, 2025, compared to a net loss of $17.8 million for the same period in 2024[14]. - The net loss for the six months ended March 31, 2025, was $21,792,751, compared to a net loss of $17,775,339 for the same period in 2024, indicating a 22.5% increase in losses[21]. - The company reported a net loss per share of $(1.27) for the three months ended March 31, 2025, compared to $(1.34) for the same period in 2024[21]. Expenses - Research and Development (R&D) expenses were $3.8 million for the quarter ended March 31, 2025, an increase from $3.6 million for the same quarter in 2024[8]. - R&D expenses related to LYMPHIR increased to $5.3 million for the six months ended March 31, 2025, compared to $3.2 million for the same period in 2024[9]. - General and Administrative (G&A) expenses rose to $4.8 million for the quarter ended March 31, 2025, up from $4.3 million for the same quarter in 2024[11]. - For the three months ended March 31, 2025, the total operating expenses were $11,260,678, an increase from $10,970,201 in the same period of 2024, representing a 2.6% increase[21]. - Research and development expenses for the three months ended March 31, 2025, were $3,766,525, up from $3,605,898 in 2024, reflecting a 4.4% increase[21]. - The company recorded stock-based compensation expense of $5,226,855 for the six months ended March 31, 2025, compared to $6,136,577 in 2024, showing a decrease of 14.8%[24]. Cash and Capital - Citius Pharmaceuticals had $26,410 in cash and cash equivalents as of March 31, 2025, and will need to secure additional capital to support operations beyond May 2025[6]. - Cash and cash equivalents at the end of the period were $26,410, a significant decrease from $12,559,607 at the end of the same period in 2024[24]. - The net cash used in operating activities for the six months ended March 31, 2025, was $(9,265,328), an improvement from $(13,921,321) in 2024, indicating a 33.5% reduction in cash outflow[24]. - The company generated net proceeds from common stock offerings amounting to $6,039,858 during the six months ended March 31, 2025[24]. - The company completed a registered direct offering that generated net proceeds of approximately $1.735 million on April 2, 2025[5]. Assets and Financial Strategy - The total assets of Citius Pharmaceuticals as of March 31, 2025, were $121.48 million, compared to $116.65 million as of September 30, 2024[19]. - The company has retained Jefferies LLC as its exclusive financial advisor to evaluate strategic alternatives aimed at maximizing stockholder value[7]. - Citius Pharmaceuticals plans to continue funding Citius Oncology until adequate capital is raised or revenue is generated from LYMPHIR sales[7]. Other Income and Shares - The total other income for the three months ended March 31, 2025, was $13,413, a decrease from $2,570,047 in the same period of 2024[21]. - The weighted average common shares outstanding for the three months ended March 31, 2025, were 8,581,207, compared to 6,362,890 in 2024, reflecting a 34.8% increase[21].

Exhibit 99.1 Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update CRANFORD, N.J., May 14, 2025 -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal second quarter ended March 31, 2025. "In Q2 2025, Citius Oncology advanced its transformation from a d ...

Exhibit 99.1 Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update CRANFORD, N.J., May 14, 2025 -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal second quarter ended March 31, 2025. "In Q2 2025, Citius Oncology advanced its transformation from a d ...

Commission file number: 001-40893 CATALYST BANCORP, INC. (Exact name of registrant as specified in its charter) Louisiana 86-2411762 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (I.R.S. Employer Identification No.) (State or other jurisdiction of incorporation of organization) 235 N. Court Street, Opelousas, Louisiana 70570 (Address of principal executive offices; Zip Code) (337) 948-3033 (Registrant's telephone number, including area code) None (Former ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Exact name of registrant as specified in its charter) FORM 10-Q (540) 951-6300 (Registrant's telephone number, including area code) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark one) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Production and Capacity - Westwater expects the Kellyton Graphite Plant to produce 12,500 metric tons of CSPG per year in Phase I, primarily for lithium-ion batteries[87] - Westwater has secured offtake agreements for 100% of its anticipated Phase I production capacity and a portion of anticipated Phase II production capacity[89] - The company produced over an 800 kg sample of CSPG for pre-production cell trials during the first quarter of 2025[94] Financial Performance - Net loss for the three months ended March 31, 2025, was $2.7 million, a decrease from a net loss of $2.9 million for the same period in 2024[113] - Net cash used in operating activities was $2.3 million for the three months ended March 31, 2025, a decrease of $0.5 million compared to the same period in 2024[118] - Net cash provided by financing activities increased by $3.7 million for the three months ended March 31, 2025, due to increased shares sold under the ATM Sales Agreement and 2024 Lincoln Park PA[122] Funding and Financial Challenges - The company is working to complete a secured debt facility for approximately $150 million to finance the completion of Phase I of the Kellyton Graphite Plant[96] - The Company's planned non-discretionary expenditures for one year exceed the cash on hand as of the date of the Interim Financial Statements[124] - The Company has faced challenges in securing additional financing due to market volatility, higher interest rates, and uncertain economic conditions[126] - The ability to raise additional funds under the ATM Sales Agreement may be limited by the Company's market capitalization, share price, and trading volume[126] - Construction activities related to the Kellyton Graphite Plant have been significantly reduced until additional funding is secured[124] Cash Position - As of March 31, 2025, the Company's cash balance was approximately $3.3 million[125] - During the three months ended March 31, 2025, the Company sold 2.5 million shares of Common Stock for net proceeds of $2.0 million and approximately 3.8 million shares for net proceeds of $2.6 million[125] - The Company has approximately $49.9 million remaining available for future sales under the ATM Sales Agreement[125] Supply Chain and Geopolitical Risks - The U.S. is almost 100% dependent on imports for battery-grade graphite, highlighting the geopolitical risks and supply-chain vulnerabilities[105][107] - Westwater is at an advanced stage in securing a backup feedstock supplier due to recent protests affecting its primary supplier[97] Forward-Looking Statements and Risks - Forward-looking statements regarding funding adequacy and operational timelines are subject to various risks and uncertainties[129] - The Company cautions that actual results may differ materially from forward-looking statements due to factors such as inflation, supply chain disruptions, and geopolitical issues[130] - The Company has no off-balance sheet arrangements[128]

EXHIBIT 99.2 Q1 2025 QUARTERLY SUPPLEMENTAL INFORMATION FrontView REIT, Inc. (NYSE: FVR) is an internally- managed net-lease REIT that acquires, owns and manages primarily properties with frontage that are net leased to a diversified group of tenants. investor.frontviewreit.com Table of Contents | Section | Page | | --- | --- | | About the Data | 3 | | Company Overview | 4 | | Quarterly Financial Summary | 5 | | Balance Sheet | 6 | | Income Statement Summary | 7 | | Funds From Operations (FFO) and Adjusted ...

GCT Semiconductor Holding, Inc. Provides Business Update and Reports First Quarter 2025 Financial Results 5G chipset sampling to customers scheduled to begin at the end of May, following completion of fab, wafer processing and delivery of finalized 5G chipsets to GCT facility SAN JOSE, CA – May 14, 2025 – GCT Semiconductor Holding, Inc. ("GCT" or the "Company") (NYSE: GCTS), a leading designer and supplier of advanced 5G and 4G semiconductor solutions, today provided an update on business developments and r ...

Financial Performance - Net revenues for Q1 2025 were $0.5 million, an 84.8% decrease from $3.3 million in Q1 2024[6] - Gross margin decreased to 17.7%, down 42.1 percentage points from 59.8% in the previous year[6] - Total operating expenses increased by 248.2% to $7.8 million, compared to a gain of $(5.3) million in Q1 2024[14] - Net loss for Q1 2025 was $(7.0) million, a 1020.5% decrease from net income of $0.8 million in Q1 2024[14] - Total assets decreased to $17.5 million as of March 31, 2025, down from $19.9 million in the previous year[18] Future Outlook - The company expects 5G chipset sampling to commence at the end of May 2025, with volume shipments anticipated to increase in the second half of the year[8] - The average selling price of 5G products is expected to be approximately four times that of 4G offerings, positively impacting revenue and gross margin[3] Financial Flexibility - The company has filed a shelf registration providing up to $200 million in capacity, including a $75 million at-the-market facility, enhancing financial flexibility[3] - Cash and cash equivalents as of March 31, 2025, were $1.0 million, with net accounts receivable of $4.5 million and inventory of $3.1 million[7] Strategic Partnerships - A letter of intent was signed with Orbic North America to jointly develop a mobile hotspot and FWA gateway utilizing a Verizon-certified 5G module[5]